The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node (N3) involvement..
The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy.
Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.
Age ≥ 18 years at time of signing the informed consent form (ICF).
Histologically or cytologically confirmed stage 3 B/C Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJCC) with pathologically-confirmed contralateral mediastinal or ipsilateral supraclavicular (N3) lymph node involvement.
Primary tumor appropriate for resection with curative intent as assessed by the treating surgeon prior to study enrollment.
Absence of major associated pathologies and co-morbidities that elevate surgery risk to a prohibitive level, as assessed by treating surgeon prior to study enrollment.
NSCLC with histology containing any of the following: large cell neuroendocrine carcinoma, small cell lung cancer.
Primary tumor not deemed appropriate for surgical resection as assessed by treating surgeon.
Tumor with direct invasion of: mediastinum, diaphragm, heart, great vessels, trachea, esophagus, vertebral body, or carina.
Any other tumor characteristic making it not suitable for resection as determined by treating surgeon.
Single group
Cemiplimab-Rwlc
Drug350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
Pathologic complete response (pCR) rate
Pathologic complete response (pCR): 0% viable tumor in primary tumor and resected lymph nodes.
Objective Response Rate (ORR)
Defined as imaging response according to RECIST v1.1 (Eisenhauer et al. 2009).
Rate of R0 Resection
Rate of R0 Resection: Defined as percentage of patients undergo complete tumor resection with negative margins.
Major pathologic response (MPR) rate
MPR Rate: Defined as the percentage of patients with resection specimen that shows ≤10% viable tumor in resected lung and lymph nodes
Disease-free Survival (DFS)
DFS: Time from first dose of neoadjuvant treatment to documented disease recurrence. Where possible, date of pathologic confirmation of recurrence should be used over date of radiographic imaging showing findings concerning for recurrence.
Click on the lead sponsor to view all of their trials.
Georgetown University
Lead sponsor
Regeneron Pharmaceuticals
Collaborator
